BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/31/2024 10:42:49 AM | Browse: 64 | Download: 151
 |
Received |
|
2024-08-20 01:10 |
|
Peer-Review Started |
|
2024-07-26 03:25 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-09-15 20:47 |
|
Revised |
|
2024-09-29 04:22 |
|
Second Decision |
|
2024-10-18 01:22 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-10-18 06:00 |
|
Articles in Press |
|
2024-10-18 06:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-10-28 01:25 |
|
Publish the Manuscript Online |
|
2024-10-31 10:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo and Zi-Li Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82474164, No. 82305046, No. 82000572 |
| Major Project of the Natural Science Research of Jiangsu Higher Education Institutions |
No. 22KJB310013 |
| Science and Technology Project of Jiangsu Province |
No. BK20200840 |
| Natural Science Foundation of Jiangsu Province |
No. BK20220467 |
|
| Corresponding Author |
Zi-Li Zhang, MD, PhD, Professor, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, Jiangsu Province, China. zilizhang@njucm.edu.cn |
| Key Words |
Liver fibrosis; Ethanol; Gut barrier function; Apoptosis; Autophagy; Peroxisome proliferator-activated receptor |
| Core Tip |
Peroxisome proliferator-activated receptor (PPAR) can inhibit the pathological process of alcohol-related liver disease (ALD). However, the dual PPARα/δ agonist elafibranor has been studied mainly in metabolic dysfunction-associated steatohepatitis and primary cholangitis, and its role in ALD and its mechanism need to be further explored. |
| Publish Date |
2024-10-31 10:42 |
| Citation |
<p>Sun YQ, Wu Y, Li MR, Wei YY, Guo M, Zhang ZL. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. <i>World J Gastroenterol</i> 2024; 30(43): 4660-4668</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i43/4660.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i43.4660 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
